Melarsoprol cyclodextrin inclusion complexes as promising oral candidates for the treatment of human African trypanosomiasis

PLoS Neglected Tropical Diseases

Volumn 5, Issue 9, 2011, Pages

  Rodgers, Jean ^a   Jones, Amy ^a   Gibaud, Stéphane ^b   Bradley, Barbara ^a   McCabe, Christopher ^a   Barrett, Michael P ^a   Gettinby, George ^c   Kennedy, Peter G E ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITÉ DE LORRAINE   (France)

^c UNIVERSITY OF STRATHCLYDE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; CYCLODEXTRIN; MELARSOMINE; MELARSONYL POTASSIUM; MELARSOPROL; TRIMELARSEN; UNCLASSIFIED DRUG; ANTIPROTOZOAL AGENT;

AFRICAN TRYPANOSOMIASIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM INFECTION; CONTROLLED STUDY; DRUG DETERMINATION; DRUG EFFICACY; DRUG STRUCTURE; FEMALE; IN VITRO STUDY; MOUSE; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARASITE LOAD; TREATMENT OUTCOME; TRYPANOSOMA BRUCEI; AFRICA SOUTH OF THE SAHARA; ANIMAL; BRAIN; CHEMICAL STRUCTURE; CHEMISTRY; DISEASE MODEL; DRUG EFFECT; DRUG SENSITIVITY; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PARASITOLOGY; PATHOLOGY; PHYSIOLOGY; RADIOGRAPHY;

ADMINISTRATION, ORAL; AFRICA SOUTH OF THE SAHARA; ANIMALS; ANTIPROTOZOAL AGENTS; BLOOD-BRAIN BARRIER; BRAIN; CYCLODEXTRINS; DISEASE MODELS, ANIMAL; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MELARSOPROL; MICE; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PARASITE LOAD; PARASITIC SENSITIVITY TESTS; TREATMENT OUTCOME; TRYPANOSOMA BRUCEI BRUCEI; TRYPANOSOMIASIS, AFRICAN;

EID: 80053451058     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0001308     Document Type: Article

References (40)

1. Kennedy PGE, (2008) The continuing problem of human African trypanosomiasis (sleeping sickness). Ann Neurol 64: 116-126.
2. Kennedy PGE, (2004) Human African trypanosomiasis of the CNS: current issues and challenges. J Clin Invest 113: 496-504.
3. Apted FIC, (1970) Clinical manifestations and diagnosis of sleeping sickness. In: Mulligan HW, editors. The African Trypanosomiases London Allen & Urwin pp. 661-683.
4. Atouguia JLM, Kennedy PGE, (2000) Neurological aspects of human African trypanosomiasis. In: Davies LE, Kennedy PGE, editors. Infectious diseases of the nervous system Oxford Butterworth-Heinemann pp. 321-372.
5. Rodgers J, (2009) Human African trypanosomiasis, chemotherapy and CNS disease. J Neuroimmunol 211: 16-22.
6. Burri C, (2010) Chemotherapy against human African trypanosomiasis: is there a road to success? Parasitology 137: 1987-1994.
7. Burri C, Nkunku S, Merolle A, Smith T, Blum J, et al. (2000) Efficacy of new, concise schedule for melarsoprol in treatment of sleeping sickness caused by Trypanosoma brucei gambiense: a randomised trial. Lancet 355: 1419-1425.
8. Opigo J, Woodrow C, (2009) NECT trial: more than a small victory over sleeping sickness. Lancet 374: 7-9.
9. WHO (1998) Control and surveillance of African trypanosomiaisis. WHO technical report series, Geneva 881: 1-113.
10. Gibaud S, Zirar SB, Mutzenhardt P, Fries I, Astier A, (2005) Melarsoprol-cyclodextrins inclusion complexes. Int J Pharm 306: 107-121.
11. Barrett MP, Boykin DW, Brun R, Tidwell RR, (2007) Human African trypanosomiasis: pharmacological re-engagement with a neglected disease. Br J Pharmacol 152: 1155-1171.
12. Pepin J, Milord F, Khonde A, Niyonsenga T, Loko L, et al. (1994) Gambiense trypanosomiasis: frequency of, and risk factors for, failure of melarsoprol therapy. Trans R Soc Trop Med Hyg 88: 447-452.
13. Soignet SL, Tong WP, Hirschfeld S, Warrell RP Jr, (1999) Clinical study of an organic arsenical, melarsoprol, in patients with advanced leukemia. Cancer Chemother Pharmacol 44: 417-421.
14. Hurst EW, (1959) The lesions produced in the central nervous system by certain organic arsenical compounds. Journal of Pathology and Bacteriology 77: 523-534.
15. Poltera AA, (1980) Immunopathological and chemotherapeutic studies in experimental trypanosomiaisis with special reference to the heart and brain. Trans R Soc Trop Med Hyg 74: 706-715.
16. Hunter CA, Jennings FW, Adams JH, Murray M, Kennedy PG, (1992) Subcurative chemotherapy and fatal post-treatment reactive encephalopathies in African trypanosomiasis. Lancet 339: 956-958.
17. Jennings FW, McNeil PE, Ndung'u JM, Murray M, (1989) Trypanosomiasis and encephalitis: possible aetiology and treatment. Trans R Soc Trop Med Hyg 83: 518-519.
18. Pepin J, Milord F, (1991) African trypanosomiasis and drug-induced encephalopathy: risk factors and pathogenesis. Trans R Soc Trop Med Hyg 85: 222-224.
19. Kennedy PGE, (2008) Diagnosing central nervous system trypanosomiasis: two stage or not to stage? Trans R Soc Trop Med Hyg 102: 306-307.
20. Loftsson T, Brewster ME, (1996) Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J Pharm Sci 85: 1017-1025.
21. Loftsson T, Duchene D, (2007) Cyclodextrins and their pharmaceutical applications. Int J Pharm 329: 1-11.
22. Raz B, Iten M, Grether-Buhler Y, Kaminsky R, Brun R, (1997) The Alamar Blue assay to determine drug sensitivity of African trypanosomes (T.b. rhodesiense and T.b. gambiense) in vitro. Acta Trop 68: 139-147.
23. Hirumi H, Hirumi K, (1989) Continuous cultivation of Trypanosoma brucei blood stream forms in a medium containing a low concentration of serum protein without feeder cell layers. J Parasitol 75: 985-989.
24. Berger BJ, Fairlamb AH, (1994) Properties of melarsamine hydrochloride (Cymelarsan) in aqueous solution. Antimicrob Agents Ch 38: 1298-1302.
25. Kennedy PGE, Rodgers J, Bradley B, Hunt SP, Gettinby G, et al. (2003) Clinical and neuroinflammatory responses to meningoencephalitis in substance P receptor knockout mice. Brain 126: 1683-1690.
26. Rodgers J, McCabe C, Gettinby G, Bradley B, Condon B, et al. (2011) Magnetic resonance imaging to assess blood-brain barrier damage in murine trypanosomiasis. Am J Trop Med Hyg 84: 344-350.
27. Abbott NJ, Chugani DC, Zaharchuk G, Rosen BR, Lo EH, (1999) Delivery of imaging agents into brain. Adv Drug Deliv Rev 37: 253-277.
28. Kennedy PGE, Rodgers J, Jennings FW, Murray M, Leeman SE, et al. (1997) A substance P antagonist, RP-67,580, ameliorates a mouse meningoencephalitic response to Trypanosoma brucei brucei. Proc Natl Acad Sci USA 94: 4167-4170.
29. Zar JH, (1996) Biostatistical analysis New Jersey Prentice Hall.
30. Barrett MP, (2010) Potential new drugs for human African trypanosomiasis: some progress at last. Curr Opin Infect Dis 23: 603-608.
31. Ben Zirar S, Astier A, Muchow M, Gibaud S, (2008) Comparison of nanosuspensions and hydroxypropyl-beta-cyclodextrin complex of melarsoprol: Pharmacokinetics and tissue distribution in mice. Eur J Pharm Biopharm.
32. Stella VJ, Rao VM, Zannou EA, Zia VV, (1999) Mechanisms of drug release from cyclodextrin complexes. Adv Drug Deliv Rev 36: 3-16.
33. Carrier RL, Miller LA, Ahmed I, (2007) The utility of cyclodextrins for enhancing oral bioavailability. J Control Release 123: 78-99.
34. Wong JW, Yuen KH, (2001) Improved oral bioavailability of artemisinin through inclusion complexation with beta- and gamma-cyclodextrins. Int J Pharm 227: 177-185.
35. Evrard B, Chiap P, DeTullio P, Ghalmi F, Piel G, et al. (2002) Oral bioavailability in sheep of albendazole from a suspension and from a solution containing hydroxypropyl-beta-cyclodextrin. J Control Release 85: 45-50.
36. FDA (2005) Guidance for Industry. Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers.
37. WHO (2007) Recommendations of the Informal Consultation on Issues for Clinical Product Development for Human African Trypanosomiasis.
38. Kennedy PGE, (2006) Diagnostic and neuropathogenesis issues in human African trypanosomiasis. Int J Parasitol 36: 505-512.
39. Lejon V, Reiber H, Legros D, Dje N, Magnus E, et al. (2003) Intrathecal immune response pattern for improved diagnosis of central nervous system involvement in trypanosomiasis. J Infect Dis 187: 1475-1483.
40. Torreele E, Bourdin TB, Tweats D, Kaiser M, Brun R, et al. (2010) Fexinidazole-a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness. PLoS Negl Trop Dis 4: e923.